依折麦布联合辛伐他汀在冠心病调脂治疗未达标患者中的效果观察  

Effectiveness of simvastatin and ezetimibe in regulating lipid for patients with coronary heart disease failing to meet lipid lowering criteria

作　　者：左国兴 王蹿蹿[1] 杜新平[1] 郑柳颖[1] 王宽[1] 王东[1] 

机构地区：[1]天津市第五中心医院心内科,天津300450

出　　处：《中国医院药学杂志》2014年第16期1385-1388,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:研究联合应用辛伐他汀和依折麦布在调脂治疗不达标冠心病患者中的应用与临床效果。方法:入选120例冠心病患者,给予辛伐他汀20 mg·d-1,每晚顿服,疗程1个月,检测患者血脂水平,根据血脂水平分为血脂达标组55例和血脂未达标组65例,达标组继续给予辛伐他汀20 mg·d-1,继续调脂治疗至第3个月;未达标组联合应用辛伐他汀20 mg·d-1和依折麦布10 mg·d-1,疗程2个月;检测所有患者调脂治疗前、调脂治疗1个月、调脂治疗3个月时胆固醇水平。结果:(1)120例冠心病患者治疗1个月后血清总胆固醇水平(TC)、低密度脂蛋白水平(LDL-C)、载脂蛋白B(ApoB)水平均显著下降(P<0.05),血脂达标率为45.83%(55/120)。(2)血脂达标组的55例患者继续调脂治疗至第3个月时与1个月时比较,TC、LDLC有上升趋势,但差异无统计学意义(P>0.05),ApoB显著上升(P<0.05)。(3)血脂未达标组治疗3个月时与1个月时比较,TC、LDL-C显著下降(P<0.05),血脂达标率为76.92%(50/65)。结论:冠心病血脂超标患者在接受辛伐他汀调脂治疗后不达标者,联合应用依折麦布进行调脂治疗,可显著降低血中胆固醇水平,减少胆固醇吸收,提高血脂达标率。OBJECTIVE To observe clinical efficacy of simvastatin combined with ezetimibe in regulating lipid for coronary heart disease（CHD） patients with single simvastatin treatment failure. METHODS 120 selected CHD patients were given simvastatin 20 mg·d -1, qd, for 1 months, and then blood lipid levels were detected. According to the results 55 cases reaching the criteria（targeted group） were given simvastatin continuously for 2 months, and 65 cases who did not reach the criteria （untargeted group） were given simvastatin 20 mg.d 1 combined with ezetimibe 10 mg·d 1 for 2 months; all patients were examined cholesterol level at baseline, 1 month and 3 months. RESULIS （1） After treatment l months, the serum total cholesterol level （TC）, low density lipoprotein （LDL-C） ,apolipoprotein B （ApoB） of 120 patients with CHD were significantly decreased （P d0. 05）, targeted rate was 45. 830/00 （55/120）. （2） TC, LDL-C level at 3 months of targeted group increased compared with 1 months （P〉0.05）, and ApoB increased significantly （P〈0. 05）. （3）TC, LDLC level at 3 months of untargeted group de creased significantly compared with 1 months （P〈0. 05）, targeted rate was 76. 92% （50/65）. CONCLUSION CHD patients with blood lipid exceeding the criteria and simply administered of simvastatin falis to meet lipid lowering criteria, added ezetimibe to which in lipid-lowering therapy can significantly lower the blood cholesterol level , reduce cholesterol absorption.

关 键 词：冠心病 依折麦布 辛伐他汀 胆固醇 血脂 

分 类 号：R969[医药卫生—药理学]